• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    L.I. Krasiliuk, R.V. Bakhchiev, M.V. Shostak, A.V. Rudenko


    About the author: L.I. Krasiliuk, R.V. Bakhchiev, M.V. Shostak, A.V. Rudenko
    Type of article Scentific article
    Annotation The study has been carried out with participation of 24 male patients, who, due to high PSA level and suspicious data previously underwent polyfocal biopsy of the prostate gland. Pathological examination of prostate biopsy samples detected no prostate cancer, high-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation focuses. All the patients were divided into two groups. The main group comprised 14 men, who during 12 months had been taken 2 capsules of nutraceuticals containing 200 mg of indole-3-carbinol (I3C) and 45 mg of epigallocatechin-3-gallate (EGCG) in the mealtime (daily dose of 400 mg I3C and 90 mg EGCG). Patients of the comparison group (10 people) were under observation. Patients of both groups followed behavioral and dietary recommendations throughout the year (recommendations EAU 2016). The LUTS index according to IPSS after 1 year of research decreased by 38.7% in the main group patients, while there were no changes in the comparison group. The total of PSA level significantly decreased by 46.2% only in patients of the main group. The data obtained in the research indicate a significant decrease in the level of PSA and LUTS with long-term use of the combination of I3C and EGCG. The previous research, conducted with the use of multivariate analysis in the molecular genetic diagnosis of preclinical stages of prostate cancer, identified a subcluster of patients with histologically confirmed BPH and the molecular genetic characteristics (as the presence and level of methylation of the promoter zone of the genes GSTP1, APC, RARb), completely relevant to PCa. Patients with histologically confirmed BPH and the molecular genetic characteristics (as the presence and level of methylation of the promoter zone of the genes GSTP1, APC, RARb), completely relevant to PCa, can be ideal focus group for targeted prevention of the development of prostate cancer with various drugs, including nutraceuticals based on I3C and EGCG.
    Tags Targeted prevention; prostate cancer; benign prostatic hyperplasia; prostate specific antigen; indole-3-carbinol; epigallocatechin-3-gallate
    • Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol. 2004; 172:1314-1317.
    • Bosland MC. How to rationally identify promising cancer chemoprevention agents? J Natl Cancer Inst. 2015; 107: 288.
    • Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15:484.
    • Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3:524.
    • Klein EA, Cooperberg MR, Magi Galluzzi C, Simko JP, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. EurUrol. 2014; 66:550–60.
    • Kostev FI, Bakhchiev RV, Krasyliuk LI. et al. The use of multivariate analysis in molecular genetic diagnosis of pre-clinical stages of prostate cancer. Experimental and Clinical Phisiology and Biochemistry. 2017; 2(1): 66-67.
    • Kristal AR, Darke AK, Morris JS, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014; 106:456.
    • Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 2014; 111:1201–12.
    • Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013; 369:603.
    • Thompson IM, Cabang AB, Wargovich MJ. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol. 2014; 11:49–60.
    • Vasileios I, Sakalis, Markos Karavitakis, Dina Bedretdinova, et al. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017; 72:757–69. doi.org/10.1016/j.eururo.2017.09.028
    • Van der Kwast TH. Prognostic prostate tissue biomarkers of potential clinical use.Virchows Arch. 2014; 464:293–300.
    Publication of the article «World of Medicine and Biology» №4(66), 2018 year, 067-070 pages, index UDK 616.65-006.6-08-039.74:615.28.
    DOI 10.26724/2079-8334-2018-4-66-67-70